Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 6, 2012

Primary Completion Date

March 15, 2013

Study Completion Date

January 24, 2014

Conditions
Chronic Hepatitis C Virus
Interventions
DRUG

Velpatasvir

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Trial Locations (10)

19139

CRI Worldwide, LLC, Philadelphia

32720

Avail Clinical Research, LLC, DeLand

32809

Orlando Clinical Research Center, Orlando

37920

New Orleans Center for Clinical Research-Knoxville, Knoxville

64131

Kansas City Gastroenterology and Hepatology, Kansas City

78215

Alamo Medical Research, San Antonio

92626

West Coast Clinical Trials, LLC, Costa Mesa

98418

Charles River Clinical Services Northwest, Inc., Tacoma

08053

CRI Worldwide, LLC, Marlton

00927

Fundacion De Investigacion De Diego, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY